DXT by RESPINOR

Novel, non-invasive ultrasound device for accurate and continuous diaphragm monitoring
Enables early detection of diaphragm dysfunction in critical care settings
Successfully validated in clinical studies on mechanically ventilated patients
Backed by substantial funding from H2020 and The Research Council of Norway
CE-marked and EN ISO 13485:2016 certified, ensuring regulatory compliance and quality
Ready for global market adoption with ongoing efforts towards US authorization
Targets a market potential of over 350 million patients across US and EU
Developed to become the technology of choice for assessing work of breathing

What is DXT?

DXT, or Diaphragm Excursion Technology, is a groundbreaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for operator-independent, continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients.

This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.

Key Benefits and Clinical Applications of DXT

Clinically proven output:
‍DXT measures diaphragm excursion (DE) and respiratory rate (RR) in real-time including trends. DXT has a well-established cut-off value to detect patients at increased risk of reintubation during the weaning process from MV.
Medical Need:
‍By identifying patients at increased risk of extubation failure during the weaning process from mechanical ventilation, RESPINOR DXT has the potential to improve decision making and reduce the number of emergency re-intubations, and potential morbidity associated with mechanical ventilation, as well as ICU and hospital length of stay.
Purpose:
‍DXT aims to optimize extubation timing, reduce re-intubation rates, improve patient outcomes, and thereby lower healthcare costs.
Technology:
DXT uses sensors with optimized design for patient comfort, continuous monitoring, and computer-aided sensor placement.
Non-Invasive:
DXT offers a non-invasive solution for monitoring diaphragm function.
Good safety profile:
A total of 389 patients been monitored with DXT through the clinical development, and no serious adverse device effects have been reported
Product:
‍RESPINOR DXT is a medical technology designed to provide an objective measure of diaphragm function.

Recent updates from RESPINOR

July 30, 2026

RESPINOR Submits De Novo Request to FDA for RESPINOR DXT®

RESPINOR submitted a De Novo Classification Request to the FDA on 30 July 2026, marking an important step toward making RESPINOR DXT® available to critical care teams in the United States.

July 30, 2026

RESPINOR Signs Distribution Agreement with Dextro Medica for the Spanish Market

The Distribution Agreement with Dextro Medica for the Spanish market was signed on 30 July 2026, marking RESPINOR’s entry into Spain and an important step in the company’s continued European expansion.

June 29, 2026

RESPINOR Secures Distributor Agreement with GADOmed for the Italian Market

June 23, 2026

RESPINOR Appoints New CFO to Support Commercial Scale-Up and International Growth

RESPINOR is pleased to announce the appointment of Sondre Bergløff as Chief Financial Officer, effective August 1, 2026.

February 12, 2026

The non-invasive ultrasound-based medical device